Introduction {#Sec1}
============

Hypoglycemia is a common problem in patients with type 2 diabetes mellitus (T2DM), occurring most frequently with anti-hyperglycemic treatments increasing insulin levels independently of the blood glucose level, such as oral insulin secretagogues \[sulfonylureas \[SUs\] and glinides\] and exogenous insulin. Hypoglycemia is associated with multiple adverse consequences that may, in some cases, counterbalance the benefit of strict glycemic control. Importantly, hypoglycemia is recognized as a major limiting factor for achieving intensive glycemic control in people with T2DM \[[@CR1], [@CR2]\] and makes clinicians less likely to implement glycemic targets \[[@CR3]\]. Hypoglycemia is also often associated with weight gain due to decreased adherence to diet with "defensive eating" to prevent and/or correct hypoglycemia \[[@CR4]\]. Furthermore, severe hypoglycemic events have been associated with an increased risk of cardiovascular complications and death \[[@CR5], [@CR6]\]. Lastly, episodes of hypoglycemia reduce adherence to therapy as well as quality of life \[[@CR7]\] and lead to increased medical costs \[[@CR8]\].

Unlike indiscriminate insulin secretagogues, such as SUs and glinides, dipeptidyl peptidase-4 (DPP-4) inhibitors regulate glucose homeostasis in a glucose-dependent manner and are, consequently, associated with a low risk of hypoglycemia \[[@CR9]\]. In addition to the glucose-dependent secretion of insulin and glucagon common to all incretin-based therapies, preservation of glucagon counter-regulation to hypoglycemia has been specifically shown for the DPP-4 inhibitor vildagliptin in several mechanistic studies and is likely a glucose-dependent insulinotropic polypeptide-mediated effect \[[@CR9]--[@CR12]\].

Clinically, the risk of hypoglycemia was compared between vildagliptin and the SU glimepiride as add-on therapy to metformin in a large, randomized, double-blind study evaluating patients with well-controlled T2DM, but not having reached target, thus being at increased risk for hypoglycemia with additional glucose-lowering therapy \[[@CR13], [@CR14]\]. In this study, patients treated with metformin (\~1,900 mg/day) and a mean baseline glycated hemoglobin (HbA~1c~) of 7.3% were randomized to receive either vildagliptin (50 mg twice daily \[bid\]) or glimepiride (titrated up to 6 mg/day), with data analyzed after 1 year (interim analysis; *n* = 2,789) \[[@CR13]\] and 2 years (*n* = 3,118) \[[@CR14]\]. While the efficacy was comparable between the two treatment arms----non-inferiority established at both timepoints----vildagliptin was associated with significant reductions in the frequency and severity of hypoglycemia. Over 1 year, confirmed hypoglycemia was reported in 1.7% of vildagliptin-treated patients (39 events) compared with 16.2% of glimepiride-treated patients (554 events, *P* \< 0.01), with 0 vs. 10 severe events (*P* \< 0.01) \[[@CR13]\]. Similar results were also seen after 2 years, with 2.3% vs. 18.2% of patients, respectively, experiencing hypoglycemia, and a 14-fold difference in the number of events \[[@CR14]\].

Given that glimepiride in the study could be titrated from a starting dose of 2 mg/day to a maximum dose of 6 mg/day, a potential limitation of the study was the perception that the hypoglycemia difference might be driven by high doses of glimepiride, although it is not known whether the risk of hypoglycemia during treatment with glimepiride is dose dependent. The purpose of the present analysis was, therefore, to compare the risk of confirmed hypoglycemia with vildagliptin to the subgroup of glimepiride-treated patients remaining on the dose of 2 mg/day throughout the study. In addition, the study provided the opportunity to assess the hypoglycemia risk of patients tolerating different dose levels of the SU to explore the potential dose dependency of the risk of hypoglycemia for glimepiride. Since differences in HbA~1c~, in particular during the initial 24 weeks of the study where glimepiride was somewhat more efficacious than vildagliptin \[[@CR13]\], could have contributed to the difference in hypoglycemia risk between the two treatments, and hypoglycemia is a particular barrier in the lower HbA~1c~ range for achieving glycemic targets, the hypoglycemia potential of the two drugs was assessed in relation to the HbA~1c~ level.

Methods {#Sec2}
=======

Patients and Study Design {#Sec3}
-------------------------

Data from the aforementioned and previously published, multicenter, randomized, double-blind study comparing vildagliptin and glimepiride were used for this analysis \[[@CR13], [@CR14]\]. In this study, patients with T2DM on stable treatment with metformin and HbA~1c~ of 6.5--8.5% were randomized 1:1 to receive vildagliptin 50 mg bid or glimepiride for 104 weeks. Glimepiride was started at a dose of 2 mg/day and could be up-titrated to a maximum of 6 mg/day.

Assessments {#Sec4}
-----------

Hypoglycemia was defined as symptoms suggestive of low blood glucose confirmed by self-monitored blood glucose (SMBG) measurement \<3.1 mmol/L plasma glucose equivalent. HbA~1c~ was measured regularly in the study and analyzed by a central laboratory (Covance Central Laboratory Services).

Data Analysis {#Sec5}
-------------

The total number of patients and demography/baseline characteristics are presented for the vildagliptin group, the glimepiride 2 mg/day, 6 mg/day and 'other' subgroups, and the overall glimepiride group for the intent-to-treat (ITT) population.

The glimepiride subgroups were defined as follows: the 2 mg/day subgroup included all patients who remained on glimepiride 2 mg/day throughout their entire study duration; the 6 mg/day subgroup included all patients who were either up-titrated to 6 mg/day by week 16 latest and subsequently stayed on this dose level throughout the remainder of their study duration or discontinued up to week 16 with 6 mg/day as their last dose; and the 'other' subgroup consisted of all remaining glimepiride-treated patients.

The reported post hoc analysis was done in the ITT population using discrete event--time modeling \[[@CR15]\], following the approach in a recently published paper \[[@CR16]\]. Hypoglycemic risk was modeled as a function of time and last-measured HbA~1c~, with treatment (or subgroup) and gender included as additional covariates. All hazard ratios (HRs) were estimated from this model, with the unadjusted hazard rates ignoring last-measured HbA~1c~ as a covariate. Further details are presented in ESM Appendix 1.

While all data over the entire study duration were used in the modeling, it was chosen to predict the hypoglycemia risk for week 24 as the minimum duration of most standard clinical trials is 24 weeks and it falls into the main period where the SU was somewhat more efficacious than vildagliptin \[[@CR13]\]. In addition, this time point ensured a more robust assessment compared with the later stages of the study when an increasing number of discontinuations occurred.

Mean changes from baseline in HbA~1c~ at week 24 in the vildagliptin group, the different glimepiride subgroups and the overall glimepiride group were analyzed using last observation carried forward in the ITT population. Within-group comparisons (endpoint vs. baseline) were made using one sample *t* test at a significance level of 0.05.

Ethics and Good Clinical Practice {#Sec6}
---------------------------------

All study participants provided written informed consent. The protocol was approved by the independent ethics committee/institutional review board at each study site or country. The study was conducted using good clinical practice and in accordance with the Declaration of Helsinki.

Results {#Sec7}
=======

Demography {#Sec8}
----------

Table [1](#Tab1){ref-type="table"} summarizes the demographic and baseline characteristics of patients in the vildagliptin 50 mg bid (*n* = 1,539), glimepiride 2 mg/day (*n* = 417), glimepiride 6 mg/day (*n* = 589), glimepiride 'other' (*n* = 514) and overall glimepiride (*n* = 1,520) groups. The demographic and baseline characteristics were overall comparable across the vildagliptin and glimepiride groups (Table [1](#Tab1){ref-type="table"}). The patients studied in the different groups had a mean age of 56--59 years, 53--54% were men and the vast majority (82--91%) were Caucasian. Mean HbA~1c~ was 7.0--7.5%, mean body mass index was 31--32 kg/m^2^ and mean duration of diagnosed T2DM was 5--6 years, with a mean duration of metformin use of 2.8--3.1 years (mean dose 1,853--1,902 mg/day). More than two-thirds of patients (64--73%) had normal renal function and renal impairment was predominantly mild in the remaining patients.Table 1Demography and baseline characteristics (ITT population)Mean ± SD or *n* (%)Vilda 50 mg bid + metforminGlim 2 mg/day + metforminGlim 6 mg/day +  metforminGlim "other" + metforminGlim "overall" + metformin*N* ^a^1,5394175895141,520Age (years)57.5 ± 9.158.9 ± 9.256.3 ± 9.357.7 ± 9.157.5 ± 9.2Sex Male815 (53.0)222 (53.2)315 (53.5)278 (54.1)815 (53.6) Female724 (47.0)195 (46.8)274 (46.5)236 (45.9)705 (46.4)Race Caucasian1,343 (87.3)380 (91.1)482 (81.8)449 (87.4)1,311 (86.3) Black18 (1.2)6 (1.4)6 (1.0)7 (1.4)19 (1.3) Asian43 (2.7)9 (2.2)13 (2.2)22 (4.3)44 (2.9) Hispanic/Latino128 (8.3)20 (4.8)79 (13.4)32 (6.2)131 (8.6) All other7 (0.5)2 (0.5)9 (1.5)4 (0.8)15 (1.0)HbA~1c~ (%)7.3 ± 0.67.0 ± 0.57.5 ± 0.77.3 ± 0.67.3 ± 0.7FPG (mmol/L)9.1 ± 2.28.2 ± 1.69.9 ± 2.49.1 ± 2.19.2 ± 2.2BMI (kg/m^2^)31.9 ± 5.331.0 ± 5.232.4 ± 5.331.6 ± 5.231.7 ± 5.3Duration of T2DM (years)5.6 ± 5.15.3 ± 4.75.9 ± 5.05.8 ± 5.45.7 ± 5.1Metformin use Duration (years)3.0 ± 2.82.8 ± 2.83.0 ± 2.83.1 ± 3.13.0 ± 2.9 Dose (mg/day)1,899 ± 4111,853 ± 3941,902 ± 4071,900 ± 4211,888 ± 409GFR (MDRD) (mL/min/1.73 m^2^) Normal (\>80)1,050 (68.2)272 (65.2)432 (73.3)330 (64.2)1,034 (68.0) Mild (≥50 to ≤80)474 (30.8)142 (34.1)153 (26.0)181 (35.2)476 (31.3) Moderate (≥30 to \<50)13 (0.8)3 (0.7)4 (0.7)3 (0.6)10 (0.7) Severe (\<30)1 (0.1)0 (0.0)0 (0.0)0 (0.0)0 (0.0) Missing1 (0.1)0 (0.0)0 (0.0)0 (0.0)0 (0.0)*BMI* body mass index, *FPG* fasting plasma glucose, *Glim* glimepiride, *GFR* glomerular filtration rate, *HbA* ~*1c*~ glycated hemoglobin, *MDRD* modification of diet in renal disease, *T2DM* type 2 diabetes mellitus, *Vilda* vildagliptin^a^ *N* (BMI) = 1,534 (Vilda 50 mg bid), 414 (Glim 2 mg/day), 588 (Glim 6 mg/day), 511 (Glim 'other') and 1,513 (Glim 'overall'); *N* (FPG) = 1,536 (Vilda 50 mg bid), 417 (Glim 2 mg/day), 588 (Glim 6 mg/day), 514 (Glim 'other') and 1,519 (Glim 'overall')

Risk of Confirmed Hypoglycemia {#Sec9}
------------------------------

The analysis showed that the risk of confirmed hypoglycemia was significantly lower in patients treated with vildagliptin 50 mg bid compared with patients who remained on glimepiride 2 mg/day for their entire study duration (2 mg/day subgroup), with similar results unadjusted \[HR = 0.04 (95% CI 0.02, 0.08); *P* \< 0.0001\] or adjusted for last-measured HbA~1c~ \[HR = 0.06 (95% CI 0.03, 0.11); *P* \< 0.0001\]. As shown in Fig. [1](#Fig1){ref-type="fig"}, the risk of hypoglycemia was very low with vildagliptin over the full HbA~1c~ range while the risk with glimepiride 2 mg/day increased with lower HbA~1c~. The increase for lower levels of HbA~1c~ was more pronounced in the glimepiride 2 mg/day subgroup than in the full set of patients treated with glimepiride (Fig. [1](#Fig1){ref-type="fig"}). The HR of vildagliptin versus the overall glimepiride group was 0.07 \[(95% CI 0.04, 0.13); *P* \< 0.0001\] unadjusted and 0.08 \[(95% CI 0.05, 0.15); *P* \< 0.0001\] adjusted for last-measured HbA~1c~.Fig. 1Risk of confirmed hypoglycemia as a function of the most recently measured glycated hemoglobin (HbA~1c~) in patients with type 2 diabetes mellitus after treatment with vildagliptin 50 mg bid + metformin (*solid line*; *n* = 1,539), glimepiride 'overall' + metformin (*dashed line*; *n* = 1,520) or glimepiride 2 mg/day + metformin (*dotted line*; *n* = 417). Risks are shown for week 24 \[intent-to-treat (ITT) population\]

To further assess the hypoglycemia risk of patients on different dose levels of glimepiride, in addition to the low-dose (2 mg/day) subgroup, analyses were also performed for the high-dose (6 mg/day) subgroup and the 'other' subgroup (comprising all remaining glimepiride-treated patients). As shown in Fig. [2](#Fig2){ref-type="fig"}, among the glimepiride groups, the 2 mg/day subgroup had the highest increase in hypoglycemia risk for lower levels of HbA~1c~, while this increase in hypoglycemia risk was least pronounced in the 6 mg/day subgroup. The 'other' subgroup had an intermediate risk, although the difference between the 2 mg/day subgroup and the 'other' subgroup was small. The HR of vildagliptin versus 6 mg/day glimepiride was 0.22 \[(95% CI 0.12, 0.43); *P* \< 0.0001\] unadjusted and 0.21 \[(95% CI 0.11, 0.40); *P* \< 0.0001\] adjusted for last-measured HbA~1c~, and this was 0.06 \[(95% CI 0.03, 0.10); *P* \< 0.0001\] and 0.07 \[(95% CI 0.04, 0.12); *P* \< 0.0001\], respectively, for the glimepiride 'other' subgroup.Fig. 2Risk of confirmed hypoglycemia as a function of the most recently measured glycated hemoglobin (HbA~1c~) in patients with type 2 diabetes mellitus after treatment with glimepiride 6 mg/day + metformin (*open diamond*; *n* = 589), glimepiride "other" + metformin (*dash dotted line*; *n* = 514) or glimepiride 2 mg/day + metformin (*dotted line*; *n* = 417). Risks are shown for week 24 \[intent-to-treat (ITT) population\]

Changes in HbA~1c~ {#Sec10}
------------------

While the hypoglycemia analyses were adjusted for last-measured HbA~1c~, for completeness, changes in HbA~1c~ were also evaluated. Figures [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"} show the hypoglycemia risk as predicted for week 24 (see "[Methods](#Sec2){ref-type="sec"}" for details); for comparison, changes in HbA~1c~ were assessed at week 24. In each group, a highly significant mean change in HbA~1c~ from baseline to week 24 was observed. The decreases in HbA~1c~ were −0.5 ± 0.02% (baseline 7.3%) in the vildagliptin 50 mg bid group, −0.6 ± 0.03% (baseline 7.0%) in the glimepiride 2 mg/day subgroup, −0.7 ± 0.03% (baseline 7.5%) in the glimepiride 6 mg/day subgroup, −0.7 ± 0.03% (baseline 7.3%) in the glimepiride 'other' subgroup and −0.7 ± 0.02% (baseline 7.3%) in the overall glimepiride group (*P* \< 0.0001 vs. baseline in all groups). Thus, the week 24 endpoint mean HbA~1c~ was \<7% (6.4--6.8%) in all groups.

Discussion {#Sec11}
==========

In a previously published study (mean HbA~1c~ 7.3%), vildagliptin (50 mg bid) showed a markedly reduced risk of hypoglycemia compared with glimepiride as add-on therapy to metformin at similar efficacy \[[@CR13], [@CR14]\]. However, since glimepiride was titrated from a starting dose of 2 mg/day to a maximum dose of 6 mg/day, one limitation of the trial was the perception that the SU dose was titrated to too high doses and the hypoglycemia difference was driven by the highest glimepiride dose of 6 mg/day. The present analysis, however, clearly showed a substantially lower risk of confirmed hypoglycemia with vildagliptin when compared with low-dose (2 mg/day) glimepiride. In addition, while all glimepiride subgroups showed a higher risk than the vildagliptin group, among the glimepiride groups the hypoglycemia risk was, against common perception, more pronounced in the glimepiride 2 mg/day subgroup than in the glimepiride 6 mg/day subgroup. Thus, the previously reported hypoglycemia results were not driven by high doses of glimepiride and an inverse relationship between the glimepiride dose and hypoglycemia risk was observed.

An additional limitation of the original study concerned the possibility that differences in HbA~1c~ reductions/levels of HbA~1c~ in particular during the initial 24 weeks of the study, where glimepiride was somewhat more efficacious than vildagliptin \[[@CR13]\], could have contributed to the difference in hypoglycemia risk between vildagliptin and glimepiride. In the present analysis, the hypoglycemia risk was, therefore, assessed in relation to the last-measured HbA~1c~ level using discrete event--time modeling. The reduced risk of hypoglycemia with vildagliptin versus glimepiride remained essentially unchanged when adjusted for the most recently measured HbA~1c~ level, as seen from the very similar HRs unadjusted and adjusted for all groups of glimepiride. Hence, it is unlikely that differences in hypoglycemic risk between the two groups can be attributed to differences in HbA~1c~ reductions. The analysis further showed that, as expected, the difference between the two treatments increased with increasingly lower HbA~1c~ levels. A limitation remains that the most recently measured HbA~1c~ value associated with the hypoglycemic event was used in the analysis, while the HbA~1c~ at the time of the hypoglycemia event was usually not available. The adjustment for last-measured HbA~1c~ was also relevant when comparing the hypoglycemia risk between the glimepiride groups as it needs to be acknowledged that the baseline HbA~1c~ level was somewhat lower in the glimepiride 2 mg/day subgroup than the glimepiride 6 mg/day subgroup; on the other hand, the glycemic levels were very low in all subgroups, so that the small differences could not have been expected to drive a major difference in hypoglycemia risk.

While the difference in hypoglycemia risk between vildagliptin and glimepiride manifests independent of the dose level, the at-first-glance unexpected finding of an inverse relationship between the glimepiride dose and hypoglycemia risk seen in the present assessment merits further comment. A potential explanation could be linked to the known attenuation of glucagon counter-regulation seen in T2DM \[[@CR17]\]; it seems reasonable to assume that this impairment in glucagon counter-regulation varies among patients secondary to a progressive reduction in the sensitivity of the α-cell to glucose. In addition, there is a variable amount of residual glucose-sensitive insulin secretion among different patients. The progression of T2DM is associated with a progressive decline in β-cell function/sensitivity \[[@CR18]\], the degree of this loss varies between different patients and some individuals have very little remaining β-cell glucose sensitivity \[[@CR19]\]. In patients with more residual β-cell sensitivity to glucose on top of the SU-induced glucose-independent insulin secretion, there is a faster postprandial β-cell response to increase insulin secretion, followed by a faster β-cell response to reduce insulin secretion when glucose levels fall \[[@CR20], [@CR21]\]. Thus, patients, who have lost much of their ability to secrete both insulin and glucagon in a glucose-sensitive manner, can be expected to be more susceptible to hypoglycemia induced by medications that stimulate insulin secretion in a glucose-independent manner. Consequently, such patients would have been more likely to have their glimepiride dose restricted to the lowest dose level of 2 mg/day in the study underlying the present analysis and even at this dose they would still have a higher risk of hypoglycemia compared with other patients with more residual glucose sensitivity. The latter patients would consequently also be more likely to tolerate high doses of SUs, which could provide an explanation for the lower hypoglycemia risk observed in the 6 mg/day subgroup compared with the 2 mg/day subgroup in the present analysis. Interestingly, a similar observation was previously made in a double-blind study comparing gliclazide modified release (MR; titrated from 30 mg/day to a maximum of 120 mg/day) and glimepiride (titrated from 1 mg/day to a maximum of 6 mg/day) \[[@CR22]\], suggesting that this could be a general finding with SUs. In both treatment groups, most hypoglycemic events occurred at the two lowest treatment doses (representing \~51% of the study population); of 22 events with gliclazide MR, there were 13 and 2 events with the 30 mg and 60 mg dose, respectively, and of 56 events with glimepiride, there were 21 and 27 events with the 1 mg and 2 mg doses, respectively \[[@CR22]\]. While patients who are less susceptible to hypoglycemia under SU treatment obviously exist, a clear limitation in clinical practice is that it is not possible to predict which patients are more or less sensitive, unless they are actually exposed to SU treatment and potential hypoglycemia to determine their hypoglycemia risk. In addition, while some patients may start with a lower risk of hypoglycemia with SUs, it is not clear what will happen over time as T2DM progresses and islet cell function further deteriorates.

In contrast to the SUs that stimulate insulin secretion in a glucose-independent manner, increase insulin capacity even at low glucose concentrations \[[@CR23], [@CR24]\] and can significantly impair glucagon counter-regulation (as shown for both tolbutamide and glibenclamide) \[[@CR25], [@CR26]\], DPP-4 inhibitors, such as vildagliptin, have been shown to stimulate insulin secretion and inhibit glucagon secretion in a glucose-dependent manner \[[@CR9]\]. In addition, at hypoglycemic levels, preserved glucagon counter-regulation has been explicitly demonstrated for vildagliptin in several studies and patient groups \[[@CR10], [@CR11], [@CR27]\]. These effects underlie the low propensity of vildagliptin to cause hypoglycemia, even at low levels of glycemia and across different patient groups and disease states \[[@CR9], [@CR28], [@CR29]\].

Conclusion {#Sec12}
==========

Taken together, the data show a substantially lower risk of confirmed hypoglycemia with vildagliptin compared with low-dose (2 mg/day) glimepiride and also reveal an inverse relationship between glimepiride dose and hypoglycemia risk. Thus, the additional analyses presented here further extend the knowledge/understanding on the differences between vildagliptin and the SU glimepiride with respect to the risk of hypoglycemia and point to interesting differences among patients with T2DM regarding the susceptibility to hypoglycemia with SUs.
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